Trial · NCT00351416
Letrozole Treatment in Normal and GnRH Deficient Women
NCT00351416, Phase 1, Phase 2, Unknown, Massachusetts General Hospital; results first posted 2017-04-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Letrozole Treatment in Normal and GnRH Deficient Women. Trials, record NCT00351416. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00351416
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Letrozole Treatment in Normal and GnRH Deficient Women
- NCT number
- NCT00351416
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Healthy Volunteers
- Interventions
- Letrozole, NAL-GLU GnRH antagonist
- First posted
- 2006-07-12
- Last updated
- 2017-07-27
- Results first posted
- 2017-04-27
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | FSH Level | EFP: average of menstrual cycle day 6 in the EFP; LFP: average of 2 days after follicle size of 16 mm | Difference in FSH peak following letrozole administration compared with control cycle |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | FSH Level | EFP: average of menstrual cycle day 6 in the EFP; LFP: average of 2 days after follicle size of 16 mm | IU/L | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| FSH Level | Aromatase Inhibitor EFP | 7.25 | Standard Error 2.42 | IU/L | |
| FSH Level | Aromatase Inhibitor LFP | 8.71 | Standard Error 1.58 | IU/L |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Aromatase Inhibitor EFP | 6 | |
| Overall Study | STARTED | Aromatase Inhibitor LFP | 9 | |
| Overall Study | COMPLETED | Aromatase Inhibitor EFP | 6 | |
| Overall Study | COMPLETED | Aromatase Inhibitor LFP | 9 | |
| Overall Study | NOT COMPLETED | Aromatase Inhibitor EFP | 0 | |
| Overall Study | NOT COMPLETED | Aromatase Inhibitor LFP | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Aromatase Inhibitor EFP | 0 | 6 |
| Total, all-cause mortality | Aromatase Inhibitor LFP | 0 | 9 |
| Total, other adverse events | Aromatase Inhibitor EFP | 0 | 6 |
| Total, other adverse events | Aromatase Inhibitor LFP | 0 | 9 |
| Total, serious adverse events | Aromatase Inhibitor EFP | 0 | 6 |
| Total, serious adverse events | Aromatase Inhibitor LFP | 0 | 6 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Aromatase Inhibitor EFP vs Aromatase Inhibitor LFP: deaths from any cause | Trial comparisons |
| Aromatase Inhibitor EFP vs Aromatase Inhibitor LFP: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00351416
GET https://conductscience.org/api/trials/v1/NCT00351416/registered